Short and long term prognosis of acute myocardial infarction since introduction of thrombolysis.

OBJECTIVE--To record prognosis and determinants of outcome in patients with acute myocardial infarction since thrombolysis was introduced. DESIGN--Observational study. SETTING--London district general hospital. PATIENTS--608 consecutive patients admitted to the coronary care unit with acute myocardial infarction between 1 January 1988 and 31 December 1991. MAIN OUTCOME MEASURE--All cause mortality, non-fatal ischaemic events (myocardial infarction, unstable angina), and revascularisation. RESULTS--Of the 608 patients, 89 (14.6%) died in hospital. 507 [corrected] patients were followed up after discharge from hospital. Mortality (95% confidence interval) at 30 days, one year, and three years was 16.0% (13.4% to 19.2%), 21.7% (18.6% to 25.2%), and 29.4% (25.3% to 33.9%) respectively. Event free survival (survival without a non-fatal ischaemic event) was 80.4% (77.0% to 83.4%) at 30 days, 66.8% (62.8% to 70.5%) at one year, and 56.1% (51.3% to 60.6%) at three years. Survival in patients treated with thrombolysis was considerably higher than in those not given thrombolysis (three year survival: 76.7% v 54.3%), although the incidence of non-fatal ischaemic events was the same in the two groups. Multivariate determinants of six month survival were left ventricular failure, treatment with thrombolysis and aspirin, smoking history, bundle branch block, and age. For patients who survived six months, age was the only factor related to long term survival. CONCLUSIONS--Although patients treated by thrombolysis had a relatively good prognosis, long term mortality and the incidence of non-fatal recurrent ischaemic events remained high. Effective strategies for the identification and treatment of high risk patients need to be reassessed.

[1]  R. Diaz,et al.  Significance of Smoking in Patients Receiving Thrombolytic Therapy for Acute Myocardial Infarction Experience Gleaned From the International Tissue Plasminogen Activator/Streptokinase Mortality Trial , 1993, Circulation.

[2]  H. White,et al.  Antecedent angina pectoris predicts worse outcome after myocardial infarction in patients receiving thrombolytic therapy: experience gleaned from the International Tissue Plasminogen Activator/Streptokinase Mortality Trial. , 1992, Journal of the American College of Cardiology.

[3]  E. Braunwald,et al.  Predictors of Early Morbidity and Mortality After Thrombolytic Therapy of Acute Myocardial Infarction: Analyses of Patient Subgroups in the Thrombolysis in Myocardial Infarction (TIMI) Trial, Phase II , 1992, Circulation.

[4]  A. Folsom,et al.  Trends in Survival of Hospitalized Myocardial Infarction Patients Between 1970 and 1985: The Minnesota Heart Survey , 1992, Circulation.

[5]  H. White,et al.  Reinfarction after thrombolytic therapy for acute myocardial infarction followed by conservative management: incidence and effect of smoking. , 1990, Journal of the American College of Cardiology.

[6]  D. Jeffries,et al.  Ineffectiveness of AL721 in HIV disease , 1990, The Lancet.

[7]  Aims Trial Study Group Long-term effects of intravenous anistreplase in acute myocardial infarction: final report of the AIMS study , 1990, The Lancet.

[8]  W. Dassen,et al.  Did prognosis after acute myocardial infarction change during the past 30 years? A meta-analysis. , 1990, Journal of the American College of Cardiology.

[9]  J. Tijssen,et al.  Long-term benefit of early thrombolytic therapy in patients with acute myocardial infarction: 5 year follow-up of a trial conducted by the Interuniversity Cardiology Institute of The Netherlands. , 1989, Journal of the American College of Cardiology.

[10]  K. Lee,et al.  Recurrent ischemia without warning. Analysis of risk factors for in-hospital ischemic events following successful thrombolysis with intravenous tissue plasminogen activator. , 1989, Circulation.

[11]  A. Albert,et al.  Short‐term risk stratification at admission based on simple clinical data in acute myocardial infarction , 1989, The American journal of cardiology.

[12]  A. M. Skene,et al.  TRIAL OF TISSUE PLASMINOGEN ACTIVATOR FOR MORTALITY REDUCTION IN ACUTE MYOCARDIAL INFARCTION Anglo-Scandinavian Study of Early Thrombolysis (ASSET) , 1988, The Lancet.

[13]  L. Bolognese,et al.  RANDOMISED TRIAL OF INTRAVENOUS STREPTOKINASE, ORAL ASPIRIN, BOTH, OR NEITHER AMONG 17 187 CASES OF SUSPECTED ACUTE MYOCARDIAL INFARCTION: ISIS-2 , 1988, The Lancet.

[14]  J. Vandenbossche,et al.  Limitations on the prognostic value of predischarge data after myocardial infarction. , 1988, British heart journal.

[15]  Aims Trial Study Group EFFECT OF INTRAVENOUS APSAC ON MORTALITY AFTER ACUTE MYOCARDIAL INFARCTION: PRELIMINARY REPORT OF A PLACEBO-CONTROLLED CLINICAL TRIAL , 1988, The Lancet.

[16]  Gruppo Italiano per lo Studio della Soprawivenza nell'Inf Miocardico. LONG-TERM EFFECTS OF INTRAVENOUS THROMBOLYSIS IN ACUTE MYOCARDIAL INFARCTION: FINAL REPORT OF THE GISSI STUDY , 1987, The Lancet.

[17]  R M Whitlock,et al.  Left ventricular end-systolic volume as the major determinant of survival after recovery from myocardial infarction. , 1987, Circulation.

[18]  A. Folsom,et al.  Improvement in long-term survival among patients hospitalized with acute myocardial infarction, 1970 to 1980. The Minnesota Heart Survey. , 1987, The New England journal of medicine.

[19]  W. Littler,et al.  Prognostic stratification of patients after myocardial infarction. , 1987, British heart journal.

[20]  E. Braunwald,et al.  Intravenous recombinant tissue-type plasminogen activator in patients with acute myocardial infarction: a report from the NHLBI thrombolysis in myocardial infarction trial. , 1986, Circulation.

[21]  M. Simoons,et al.  IMPROVED SURVIVAL AFTER EARLY THROMBOLYSIS IN ACUTE MYOCARDIAL INFARCTION A Randomised Trial by the Interuniversity Cardiology Institute in The Netherlands , 1985, The Lancet.

[22]  R. Peto,et al.  Beta blockade during and after myocardial infarction: an overview of the randomized trials. , 1985, Progress in cardiovascular diseases.

[23]  S. M. Collins,et al.  Rethrombosis after reperfusion with streptokinase: importance of geometry of residual lesions. , 1984, Circulation.

[24]  C. Wild,et al.  Prognosis after recovery from first acute myocardial infarction: determinants of reinfarction and sudden death. , 1984, The American journal of cardiology.

[25]  M. Hobbs,et al.  Long-term prognosis after recovery from myocardial infarction: a nine year follow-up of the Perth Coronary Register. , 1983, Circulation.

[26]  B. Wolffenbuttel,et al.  Significance of haemodynamic variables in coronary care unit for prediction of survival after acute myocardial infarction. , 1983, British heart journal.

[27]  J. Miller,et al.  Long-term prognosis after first Q-wave (transmural) or non-Q-wave (nontransmural) myocardial infarction: analysis of 593 patients. , 1983, The American journal of cardiology.

[28]  G. Sanz,et al.  Determinants of prognosis in survivors of myocardial infarction: a prospective clinical angiographic study. , 1982, The New England journal of medicine.

[29]  P. Siltanen,et al.  Five-year survival of 728 patients after myocardial infarction. A community study. , 1980, British heart journal.

[30]  J W Covell,et al.  Prognosis After Acute Myocardial Infarction A Multivariate Analysis of Mortality and Survival , 1979, Circulation.

[31]  R. W. Brower,et al.  Prediction of 1-year outcome after complicated and uncomplicated myocardial infarction: Bayesian analysis of predischarge exercise test results in 300 patients. , 1987, American heart journal.

[32]  A prospective trial of intravenous streptokinase in acute myocardial infarction (I.S.A.M.). Mortality, morbidity, and infarct size at 21 days. , 1986, The New England journal of medicine.

[33]  David R. Cox,et al.  Regression models and life tables (with discussion , 1972 .